Impact of a Predictive Score of Bowel Preparation Quality in Clinical Practice

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

260 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-04

Study Completion Date

2019-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single center randomized controlled trial to compare the colon cleansing quality determined by the Boston Bowel Preparation Scale achieved by two strategies in patients with high risk of poor colon cleansing defined as those patients with a score\> 1.225 following a predictive score previously published: one group will receive an intensified split-dose 4 L polyethylene glycol solution (PEG) plus bisacodyl and 3 days of fiber-free diet and the other group a split-dose 2 L PEG solution with ascorbic plus bisacodyl and 1 day of fiber-free diet.

Patients with a score ≤ 1.225 will receive a split-dose 2 L PEG solution with ascorbic plus bisacodyl and 1 day of fiber-free diet.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid.

NCT02073552

Colonoscopy Preparation

COMPLETED PHASE4

Patient and Colonoscopy Cleansing Quality Agreement

NCT04702646

Cleansing Quality of the Colon

COMPLETED

Comparison of 1 Liter PEG With Ascorbate and Sodium Picosulfate / Magnesium Citrate for High Quality Colon Cleansing

NCT04598880

Colonic Diseases

UNKNOWN PHASE4

1L- vs. 4L-PEG for Bowel Preparation Among Inpatients.

NCT04310332

Colonoscopy Hospitalized Patients Bowel Preparation

COMPLETED

Comparison Between OSS and 2L PEG/Asc for Bowel Preparation of Elderly People

NCT03520361

Colonoscopy

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, randomized, single-blind phase IV study in which all outpatients scheduled for a colonoscopy will be given a different bowel cleansing strategy (conventional or intensified) according to a scoring system already validated in the investigator's center, designed with variables independently associated with poor bowel cleansing, constipation, abdominal/pelvic surgery, comorbidity and to be on antidepressant treatment. According to this system, a score equal to or less than 1.225, predicts with a high confidence (negative predictive value = 88%) a suitable cleansing quality with a standard preparation protocol. Therefore, these subjects will be advised of a conventional preparation (low fiber diet the day before the examination and low volume preparation consisting of 2 L of PEG with ascorbic acid). Subjects with a score greater than 1.225 will be randomized to receive an intensive bowel preparation (low fiber diet three days prior to colonoscopy and large bowel preparation consisting of 4 L PEG with bisacodyl) or a conventional one (low fiber diet the day before the examination and 2 L of PEG with ascorbic acid). The choice of low-volume preparation as a control is supported by the absence of significant differences in quality of cleanliness in patients with a score \> 1.225 among patients prepared with high or low volume and that low volume preparation appears to improve tolerance and compliance.

A researcher will offer to participate in the study to all outpatients with a scheduled colonoscopy, who meet all the inclusion criteria and none of the exclusion criteria. The researchers will explain the purpose of the study and will ask to sign the informed consent. They will give verbal and written information on the bowel preparation strategy. Thus, according to the allocation group, participants must comply with a large volume cleansing strategy or a conventional one. For patients with a low score (≤ 1.225) a conventional preparation will be recommended.

Patients must complete a baseline questionnaire at the inclusion visit and another questionnaire at the colonoscopy visit.

The hypothesis of the study is that in patients with a high risk of poor bowel preparation, the large bowel based preparation strategy is superior to the conventional bowel preparation in achieving an acceptable bowel cleansing assessed by a validated scale (Boston Bowel Preparation Score).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cleansing Quality of the Colon

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Investigators

Only the endoscopists in charge of rating the bowel cleansing during the colonoscopy will be masked

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Large volume based preparation

This strategy will consist of split dose 4 L polyethylene glycol plus 10 mg bisacodyl plus 3 days of fiber-free diet.

Group Type EXPERIMENTAL

polyethylene glycol

Intervention Type DRUG

The experimental arm will take 4 L polyethylene glycol solution (PEG) in split dose plus bisacodyl and 3 days of fiber-free diet

Low volume based preparation

This strategy will consist of split dose 2 L polyethylene glycol plus Ascorbic acid plus 1 day of fiber-free diet

Group Type ACTIVE_COMPARATOR

polyethylene glycol plus ascorbic acid

Intervention Type DRUG

The control arm will take 2 L polyethylene glycol solution (PEG) plus ascorbic acid in split dose plus 1 day of fiber-free diet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

polyethylene glycol

The experimental arm will take 4 L polyethylene glycol solution (PEG) in split dose plus bisacodyl and 3 days of fiber-free diet

Intervention Type DRUG

polyethylene glycol plus ascorbic acid

The control arm will take 2 L polyethylene glycol solution (PEG) plus ascorbic acid in split dose plus 1 day of fiber-free diet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Outpatient colonoscopy
* Willing to participate (informed consent signed).

Exclusion Criteria

* Intestinal perforation
* Poorly controlled arterial hypertension (HTAS\> 180 HTAD\> 100)
* Congestive heart failure
* NYHA III-IV
* Acute hepatic failure
* End-stage renal disease (creatinine \<15 ml / min dialysis or pre-dialysis)
* Pregnancy or breastfeeding
* Known hypersensitivity reaction to drug components
* Phenylketonuria or Glucose-6-phosphate dehydrogenase deficiency
* Dementia with difficulty in intake of Preparation
* Past history of poor bowel preparation colonic cleanliness
* Inability to follow the instructions

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No